PSP Research LLC Purchases Shares of 31,762 Denali Therapeutics Inc. $DNLI

Posted by Brenda Bartman on May 20th, 2026

PSP Research LLC purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 31,762 shares of the company’s stock, valued at approximately $524,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Denali Therapeutics by 8.9% in the 4th quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after buying an additional 1,064,972 shares during the last quarter. Baillie Gifford & Co. increased its holdings in shares of Denali Therapeutics by 6.2% in the 4th quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock worth $203,253,000 after buying an additional 719,304 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Denali Therapeutics by 12.2% in the 3rd quarter. Alliancebernstein L.P. now owns 3,520,414 shares of the company’s stock worth $51,116,000 after buying an additional 383,274 shares during the last quarter. Holocene Advisors LP increased its holdings in shares of Denali Therapeutics by 677.8% in the 3rd quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock worth $45,531,000 after buying an additional 2,732,540 shares during the last quarter. Finally, UBS Group AG increased its holdings in shares of Denali Therapeutics by 19.5% in the 4th quarter. UBS Group AG now owns 2,404,704 shares of the company’s stock worth $39,702,000 after buying an additional 392,351 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on DNLI. Wall Street Zen upgraded shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Morgan Stanley reduced their target price on shares of Denali Therapeutics from $42.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. Wedbush reduced their target price on shares of Denali Therapeutics from $25.00 to $23.00 and set an “outperform” rating on the stock in a report on Friday, May 8th. Robert W. Baird boosted their target price on shares of Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Finally, Wolfe Research assumed coverage on shares of Denali Therapeutics in a report on Monday, February 23rd. They issued a “peer perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $35.00.

View Our Latest Analysis on Denali Therapeutics

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $18.09 on Wednesday. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of -6.28 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. Denali Therapeutics Inc. has a 1 year low of $12.58 and a 1 year high of $23.77. The firm has a 50-day moving average of $19.93 and a two-hundred day moving average of $19.02.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.04. During the same quarter in the previous year, the firm earned ($0.78) earnings per share. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.74 earnings per share for the current year.

Denali Therapeutics Profile

(Free Report)

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.